Sugi Predict

Sugi Predict / Compounds / SCHEMBL641359

SCHEMBL641359

SCHEMBL641359

Oc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1

nearest known ligand 0.75

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 16/20 0.75
▸ ERBB2 P04626 3/20 0.65
▸ RAF1 P04049 1/20 0.65
▸ BRAF P15056 1/20 0.65
▸ GRM1 Q13255 1/20 0.65
▸ FBP1 P09467 2/20 0.63
▸ AURKA O14965 1/20 0.63
▸ INSR P06213 1/20 0.63
▸ PDGFRB P09619 1/20 0.63
▸ FLT4 P35916 1/20 0.63
▸ KDR P35968 1/20 0.63
▸ CLK1 P49759 1/20 0.63
▸ EPHB4 P54760 1/20 0.63
▸ TEK Q02763 1/20 0.63
▸ AURKB Q96GD4 1/20 0.63
▸ CD38 P28907 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7763004 0.88 ALK (0.60) EGFRERBB2RAF1BRAFKDR
SCHEMBL6188729 0.86 EGFR (0.77) EGFRERBB2GRM1FBP1AURKA
SCHEMBL5843772 0.86 EGFR (0.69) EGFRERBB2RAF1BRAFGRM1
SCHEMBL31299934 0.86 EGFR (1.00) EGFRERBB2RAF1BRAFGRM1
SCHEMBL29923578 0.86 EGFR (1.00) EGFRERBB2RAF1BRAFGRM1
SCHEMBL2991833 0.86 EGFR (1.00) EGFRERBB2RAF1BRAFGRM1
Hydrochloric Acid SCHEMBL6190330 0.85 EGFR (0.75) EGFRERBB2GRM1FBP1AURKA
SCHEMBL21083167 0.85 EGFR (0.75) EGFRERBB2RAF1BRAFGRM1
SCHEMBL1734677 0.85 EGFR (0.75) EGFRERBB2RAF1BRAFGRM1
Hydrochloric Acid SCHEMBL7764930 0.85 EGFR (0.97) EGFRERBB2RAF1BRAFGRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150284340-A1 QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS INC (US) 2015-10-08 — — US disclosed
US-20150274678-A1 QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS INC (US) 2015-10-01 — — US disclosed
US-9108929-B2 Quinazoline based EGFR inhibitors CURIS, INC. (US) 2015-08-18 — — US disclosed
US-9024024-B2 Quinazoline based EGFR inhibitors containing a zinc binding moiety CURIS, INC. (US) 2015-05-05 — — US disclosed
US-8975401-B2 Quinazoline based EGFR inhibitors containing a zinc binding moiety CURIS, INC. (US) 2015-03-10 — — US disclosed
EP-2190287-B1 TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS INC (US) 2014-10-29 — — EP disclosed
US-8846912-B2 Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety CURIS, INC. (US) 2014-09-30 — — US disclosed
US-20140221403-A1 QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. (US) 2014-08-07 — — US disclosed
US-20140155606-A1 QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY CURIS, INC. (US) 2014-06-05 — — US disclosed
US-20140005391-A1 QUINAZOLINE BASED EGFR INHIBITORS CURIS, INC. (US) 2014-01-02 — — US disclosed
US-20030018029-A1 Quinazoline derivatives ZENECA LIMITED 2003-01-23 — — US disclosed
US-6399602-B1 ANTICANCER AGENTS ZENECA LIMITED (GB) 2002-06-04 — — US disclosed
EP-0824525-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2001-06-13 — — EP disclosed
US-5932574-A ANTICANCER AGENT ZENECA LIMITED (GB) 1999-08-03 — — US disclosed
CN-1211240-A Quinazoline derivatives as antitumor agents ZENECA LTD (GB) 1999-03-17 — — CN disclosed
US-5866572-A RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES, TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER. ZENECA LIMITED (GB) 1999-02-02 — — US disclosed
EP-0880507-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ZENECA LIMITED (GB) 1998-12-02 — — EP disclosed
EP-0824525-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1998-02-25 — — EP disclosed
WO-1997030034-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ZENECA LIMITED (GB) 1997-08-21 — — WO disclosed
WO-1996033977-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1996-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018029-A1 Quinazoline derivatives ABL1, FGFR1, ERBB2 EGFR 25/4885ERBB2 3/4885RAF1 7/4885
US-20140221403-A1 QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY EGFR, HDAC5, ERBB4 EGFR 1/4885ERBB2 7/4885RAF1 159/4885
US-20140155606-A1 QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY EGFR, HDAC1, HDAC5 EGFR 1/4885ERBB2 5/4885RAF1 139/4885
US-20140005391-A1 QUINAZOLINE BASED EGFR INHIBITORS EGFR, ERBB2, ERBB4 EGFR 1/4885ERBB2 2/4885RAF1 51/4885
US-20150274678-A1 QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY EGFR, HDAC1, HDAC5 EGFR 1/4885ERBB2 5/4885RAF1 139/4885
US-20150284340-A1 QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY EGFR, ERBB4, HDAC5 EGFR 1/4885ERBB2 7/4885RAF1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.